Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Lymphoma, Non-Hodgkin 6Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Multiple Myeloma 2Lymphoma, Follicular 2Endometrial Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Spinocerebellar Degenerations 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Renal Insufficiency 1Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Malignant Solid Neoplasm 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hepatic Insufficiency 1Gallbladder Neoplasms 1Digestive System Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 5lenvatinib 3cabozantinib 3Sunitinib 3Iodine-131 3trametinib 2selpercatinib 2dabrafenib 2Sorafenib 2Fluorodeoxyglucose F18 2AZD 6244 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2vandetanib 1tremelimumab 1tovorafenib 1tanespimycin 1romidepsin 1pralsetinib 1pembrolizumab 1omipalisib 1durvalumab 1copanlisib 1cediranib 1alectinib 1aflibercept 1Vorinostat 1Vemurafenib 1Thyrotropin Alfa 1Thyroidectomy 1Thyroid (USP) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thyroid Cancer, Papillary × copanlisib × Clear all
NCT04462471 2025-09-08

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
8 enrolled 8 charts
EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡